BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
February 05, 2025 18:15 ET | Source: BriaCell Therapeutics Corp. PHILADELPHIA, Pa.…
Viracta Therapeutics Announces Wind Down of Operations
February 05, 2025 17:00 ET | Source: Viracta Therapeutics, Inc. SAN DIEGO,…
BriaCell Therapeutics Announces Pricing of Public Offering
February 03, 2025 19:59 ET | Source: BriaCell Therapeutics Corp. PHILADELPHIA and…
Maze Therapeutics Announces Pricing of Upsized Initial Public Offering
January 30, 2025 19:30 ET | Source: Maze Therapeutics, Inc. SOUTH SAN…
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion”…
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025 16:05 ET | Source: Akero Therapeutics Inc. Investor webcast…
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025 16:05 ET | Source: Akero Therapeutics Inc. Investor webcast…
Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in Hepatocellular Carcinoma
January 24, 2025 10:41 ET | Source: Elevar Therapeutics Post-hoc analysis on…
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreichs Ataxia
January 23, 2025 16:05 ET | Source: Larimar Therapeutics Adolescents receive a…
Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with Atr
January 22, 2025 17:00 ET | Source: Anthos Therapeutics Secondary endpoints also…